Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
Kim AE, Lou KW, Giobbie-Hurder A, Chang K, Gidwani M, Hoebel K, Patel JB, Cleveland MC, Singh P, Bridge CP, Ahmed SR, Bearce BA, Liu W, Fuster-Garcia E, Lee EQ, Lin NU, Overmoyer B, Wen PY, Nayak L, Cohen JV, Dietrich J, Eichler A, Heist R, Krop I, Lawrence D, Ligibel J, Tolaney S, Mayer E, Winer E, Perrino CM, Summers EJ, Mahar M, Oh K, Shih HA, Cahill DP, Rosen BR, Yen YF, Kalpathy-Cramer J, Martinez-Lage M, Sullivan RJ, Brastianos PK, Emblem KE, Gerstner ER.
Kim AE, et al. Among authors: summers ej.
Neuro Oncol. 2024 May 3;26(5):965-974. doi: 10.1093/neuonc/noad236.
Neuro Oncol. 2024.
PMID: 38070147
Clinical Trial.